Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic

References

• Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, Crosby AE, Paulozzi LJ. Patterns of abuse among unintentional pharmaceutical overdose fatalities. Jama. 2008;300:2613–20.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370:2063–66. doi:10.1056/NEJMp1402780.
   PubMed Web of Science ®Google Scholar
• National Institute on Drug Abuse. Prescription opioids and heroin. Rockville, MD: National Institute for Drug Abuse; 2018. Available from: https://www.drugabuse.gov/node/pdf/19774/prescription-opioids-and-heroin [last accessed 12 Jan 2020].
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document. HHS Publication No. (SMA) 18-5063FULLDOC.Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018.
   Google Scholar
• Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9:358. doi:10.1097/ADM.0000000000000166.
   PubMed Web of Science ®Google Scholar
• Society for Community Research and Action. The role of recovery residences in promoting long-term addiction recovery. Am J Community Psychol. 2013;52:406–11. doi:10.1007/s10464-013-9602-6.
   PubMed Web of Science ®Google Scholar
• Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain. 2012;6:11–16. doi:10.1177/2049463712438493.
   PubMedGoogle Scholar
• Weis WI, Kobilka BK. The molecular basis of G protein–coupled receptor activation. Annu Rev Biochem. 2018;87:897–919. doi:10.1146/annurev-biochem-060614-033910.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Lib. 2009;(3):1–32.
   Google Scholar
• Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506–13. doi:10.1016/S0140-6736(11)60358-9.
   PubMed Web of Science ®Google Scholar
• Tanum L, Solli KK, Latif Z-EH, JŠ B, Opheim A, Sharma-Haase K, Krajci P, Kunøe N. The effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry. 2017;74:1197.
   PubMed Web of Science ®Google Scholar
• Lee JD, Jr EV N, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, King J. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391:309–18.
   PubMed Web of Science ®Google Scholar
• Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano LB, Dougherty RH, Daniels AS, Ghose SS, Delphin-Rittmon ME. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv. 2014;65:146–57.
   PubMed Web of Science ®Google Scholar
• Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, Daniels AS, Ghose SS, Delphin-Rittmon ME. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014;65:158–70.
   PubMed Web of Science ®Google Scholar
• Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31:207–25. doi:10.1080/10550887.2012.694598.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren J. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta‐analysis of cohort studies. Addiction. 2011;106:32–51.
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169:137–45.
   PubMed Web of Science ®Google Scholar
• Ma J, Bao Y-P, Wang R-J, Su M-F, Liu M-X, Li J-Q, Degenhardt L, Farrell M, Blow FC, Ilgen M, Shi J. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2019;24:1868–83.
   PubMed Web of Science ®Google Scholar
• Mojtabai R, Mauro C, Wall MM, Barry CL, Olfson M. Medication treatment for opioid use disorders in substance use treatment facilities. Health Aff. 2019;38:14–23. doi:10.1377/hlthaff.2018.05162.
   PubMed Web of Science ®Google Scholar
• Jones C, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105:e55–e63. doi:10.2105/AJPH.2015.302664.
   PubMed Web of Science ®Google Scholar
• Abraham AJ, Knudsen HK, Rieckmann T, Roman PM. Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States. J Stud Alcohol Drugs. 2013;74:258–65. doi:10.15288/jsad.2013.74.258.
   PubMed Web of Science ®Google Scholar
• Aletraris L, Edmond MB, Roman PM. Adoption of injectable naltrexone in US substance use disorder treatment programs. J Stud Alcohol Drugs. 2015;76:143–51. doi:10.15288/jsad.2015.76.143.
   PubMed Web of Science ®Google Scholar
• Fareed A, Eilender P, Ketchen B, Buchanan-Cummings AM, Scheinberg K, Crampton K, Nash A, Shongo-Hiango H, Drexler K. Factors affecting noncompliance with buprenorphine maintenance treatment. J Addict Med. 2014;8:345–50.
   PubMed Web of Science ®Google Scholar
• Molfenter T, Sherbeck C, Zehner M, Quanbeck A, McCarty D, Kim J-S, Starr S. Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio. Subst Abuse Treat Prev Policy. 2015;10:13.
   PubMed Web of Science ®Google Scholar
• Volkow ND. Medications for opioid use disorder: bridging the gap in care. Lancet. 2018;391:285–87. doi:10.1016/S0140-6736(17)32893-3.
   PubMed Web of Science ®Google Scholar
• Sharma A, Kelly SM, Mitchell SG, Gryczynski J, O’Grady KE, Schwartz RP. Update on barriers to pharmacotherapy for opioid use disorders. Curr Psychiatry Rep. 2017;19:35. doi:10.1007/s11920-017-0783-9.
   PubMed Web of Science ®Google Scholar
• Allen B, Nolan ML, Paone D. Underutilization of medications to treat opioid use disorder: what role does stigma play? Subst Abuse. 2019;40(4):459–65.
   PubMedGoogle Scholar
• Woo J, Bhalerao A, Bawor M, Bhatt M, Dennis B, Mouravska N, Zielinski L, Samaan Z. “Don’t judge a book by its cover”: a qualitative study of methadone patients’ experiences of stigma. Subst Abuse. 2017;11:1178221816685087.
   Web of Science ®Google Scholar
• Wakeman SE, Rich JD. Barriers to medications for addiction treatment: how stigma kills. Subst Use Misuse. 2018;53:330–33. doi:10.1080/10826084.2017.1363238.
   PubMed Web of Science ®Google Scholar
• Brewer DD, Catalano RF, Haggerty K, Gainey RR, Fleming CB. A meta‐analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction. 1998;93:73–92. doi:10.1046/j.1360-0443.1998.931738.x.
   PubMed Web of Science ®Google Scholar
• Scherbaum N, Specka M. Factors influencing the course of opiate addiction. Int J Methods Psychiatr Res. 2008;17:S39–S44. doi:10.1002/(ISSN)1557-0657.
   PubMed Web of Science ®Google Scholar
• Schwartz RP, Kelly SM, O’Grady KE, Mitchell SG, Brown BS. Antecedents and correlates of methadone treatment entry: a comparison of out-of-treatment and in-treatment cohorts. Drug Alcohol Depend. 2011;115:23–29. doi:10.1016/j.drugalcdep.2010.10.016.
   PubMed Web of Science ®Google Scholar
• Cloud W, Granfield R. Conceptualizing recovery capital: expansion of a theoretical construct. Subst Use Misuse. 2008;43:1971–86. doi:10.1080/10826080802289762.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services (HHS) Office of the Surgeon General. Facing addiction in America: the surgeon general’s report on alcohol, drugs, and health. Washington, DC: US Department of Health and Human Services; 2016.
   Google Scholar
• Ferrari JR, Jason LA, Olson BD, Davis MI, Alvarez J. Sense of community among Oxford House residents recovering from substance abuse: making a house a home. In: Fisher A, Sonn C, Bishop B, editors. The Plenum series in social/clinical psychology psychological sense of community: research, applications, and implications. New York, NY: Kluwer Academic/Plenum Publishers; 2002:109–22.
   Google Scholar
• Jason LA, Davis MI, Ferrari JR. The need for substance abuse after-care: longitudinal analysis of Oxford House. Addict Behav. 2007;32:803–18. doi:10.1016/j.addbeh.2006.06.014.
   PubMed Web of Science ®Google Scholar
• Oxford House International. History and accomplishments; 2019. Available from: https://www.oxfordhouse.org/userfiles/file/oxford_house_history.php [last accessed 12 Jan 2020].
   Google Scholar
• National Alliance for Recovery Residences. About Us; 2019. Available from: https://narronline.org/about-us/ [last accessed 12 Jan 2020].
   Google Scholar
• National Alliance for Recovery Residences. A primer on recovery residences: FAQs; 2012. .
   Google Scholar
• Jason LA, Olson BD, Ferrari JR, Lo Sasso AT. Communal housing settings enhance substance abuse recovery. Am J Public Health. 2006;96:1727–29. doi:10.2105/AJPH.2005.070839.
   PubMed Web of Science ®Google Scholar
• Polcin DL, Korcha R, Bond J, Galloway G. What did we learn from our study on sober living houses and where do we go from here? J Psychoactive Drugs. 2010;42:425–33. doi:10.1080/02791072.2010.10400705.
   PubMed Web of Science ®Google Scholar
• Mericle AA, Miles J, Cacciola J. A critical component of the continuum of care for substance use disorders: recovery homes in Philadelphia. J Psychoactive Drugs. 2015;47:80–90. doi:10.1080/02791072.2014.976726.
   PubMed Web of Science ®Google Scholar
• Malivert M, Fatséas M, Denis C, Langlois E, Auriacombe M. Effectiveness of therapeutic communities: a systematic review. Eur Addict Res. 2012;18:1–11. doi:10.1159/000331007.
   PubMed Web of Science ®Google Scholar
• Reif S, George P, Braude L, Dougherty RH, Daniels AS, Ghose SS, Delphin-Rittmon ME. Recovery housing: assessing the evidence. Psychiatr Serv. 2014;65:295–300.
   PubMed Web of Science ®Google Scholar
• Tuten M, DeFulio A, Jones HE, Stitzer M. Abstinence‐contingent recovery housing and reinforcement‐based treatment following opioid detoxification. Addiction. 2012;107:973–82. doi:10.1111/add.2012.107.issue-5.
   PubMed Web of Science ®Google Scholar
• Tuten M, Shadur JM, Stitzer M, Jones HE. A comparison of reinforcement based treatment (RBT) versus RBT plus recovery housing (RBTRH). J Subst Abuse Treat. 2017;72:48–55. doi:10.1016/j.jsat.2016.09.001.
   PubMed Web of Science ®Google Scholar
• Majer JM, Beasley C, Stecker E, Bobak TJ, Norris J, Nguyen HM, Ogata M, Siegel J, Isler B, Wiedbusch E, Jason LA. Oxford House residents’ attitudes toward medication assisted treatment use in fellow residents. Community Ment Health J. 2018;54(5):571–77.
   Web of Science ®Google Scholar
• Mericle AA, Hemberg J, Stall R, Carrico AW. Pathways to recovery: recovery housing models for men who have sex with men (MSM). Addict Res Theory. 2019;27:373–82. doi:10.1080/16066359.2018.1538409.
   PubMed Web of Science ®Google Scholar
• Rinker B. Recovery residences combat addiction in rural communities. Health Aff. 2019;38:1968–70. doi:10.1377/hlthaff.2019.01489.
   Web of Science ®Google Scholar
• Andersson HW, Wenaas M, Nordfjærn T. Relapse after inpatient substance use treatment: a prospective cohort study among users of illicit substances. Addict Behav. 2019;90:222–28. doi:10.1016/j.addbeh.2018.11.008.
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. bmj. 2017;357:j1550.
   PubMed Web of Science ®Google Scholar
• Tkacz J, Severt J, Cacciola J, Ruetsch C. Compliance with buprenorphine medication‐assisted treatment and relapse to opioid use. Am J Addict. 2012;21:55–62. doi:10.1111/ajad.2012.21.issue-1.
   PubMed Web of Science ®Google Scholar
• Borkman T, Kaskutas LA, Room J, Bryan K, Barrows D. An historical and developmental analysis of social model programs. J Subst Abuse Treat. 1998;15:7–17. doi:10.1016/S0740-5472(97)00244-4.
   PubMed Web of Science ®Google Scholar
• Mericle AA, Polcin DL, Hemberg J, Miles J. Recovery housing: evolving models to address resident needs. J Psychoactive Drugs. 2017;49:352–61. doi:10.1080/02791072.2017.1342154.
   PubMed Web of Science ®Google Scholar
• Barry CL, McGinty EE, Pescosolido BA, Goldman HH. Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness. Psychiatr Serv. 2014;65:1269–72. doi:10.1176/appi.ps.201400140.
   PubMed Web of Science ®Google Scholar
• Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder—and its treatment. Jama. 2014;311:1393–94. doi:10.1001/jama.2014.2147.
   PubMed Web of Science ®Google Scholar
• Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: health services experiences among people who inject drugs. Int J Drug Policy. 2018;57:104–10. doi:10.1016/j.drugpo.2018.04.004.
   PubMed Web of Science ®Google Scholar
• Haffajee RL, Bohnert AS, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54:S230–S42. doi:10.1016/j.amepre.2017.12.022.
   PubMed Web of Science ®Google Scholar
• Friedmann PD, Jr R H, Gordon M, Schwartz R, Kinlock T, Knight K, Flynn PM, Welsh WN, Stein LA, Sacks S, O’Connell DJ. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abuse. 2012;33:9–18.
   PubMed Web of Science ®Google Scholar
• Matusow H, Dickman SL, Rich JD, Fong C, Dumont DM, Hardin C, Marlowe D, Rosenblum A. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44:473–80.
   PubMed Web of Science ®Google Scholar
• Wakeman SE. Why it’s inappropriate not to treat incarcerated patients with opioid agonist therapy. AMA J Ethics. 2017;19:922–30.
   PubMedGoogle Scholar
• Rieckmann T, Daley M, Fuller BE, Thomas CP, McCarty D. Client and counselor attitudes toward the use of medications for treatment of opioid dependence. J Subst Abuse Treat. 2007;32:207–15. doi:10.1016/j.jsat.2006.09.002.
   PubMed Web of Science ®Google Scholar
• White WL. Narcotics Anonymous and the pharmacotherapeutic treatment of opioid addiction in the United States. Chicago, IL: Philadelphia Department of Behavioral Health and Intellectual Disability Services & Great Lakes Addiction Technology Transfer Center; 2011.
   Google Scholar
• Maxwell JC, McCance‐Katz EF. Indicators of buprenorphine and methadone use and abuse: what do we know? Am J Addict. 2010;19:73–88. doi:10.1111/j.1521-0391.2009.00008.x.
   PubMed Web of Science ®Google Scholar
• Fox AD, Chamberlain A, Sohler NL, Frost T, Cunningham CO. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. J Subst Abuse Treat. 2015;48:112–16. doi:10.1016/j.jsat.2014.07.015.
   PubMed Web of Science ®Google Scholar
• Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8:315. doi:10.1097/ADM.0000000000000045.
   PubMed Web of Science ®Google Scholar
• Weiss F, Ciccocioppo R, Parsons LH, Katner S, Liu X, Zorrilla EP, Valdez GR, BEN‐SHAHAR OS, Angeletti S, Richter RR. Compulsive drug‐seeking behavior and relapse: neuroadaptation, stress, and conditioning factors. Ann N Y Acad Sci. 2001;937:1–26.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374:363–71. doi:10.1056/NEJMra1511480.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Nuzzo PA, Babalonis S, Casselton V, Lofwall MR. Intranasal buprenorphine alone and in combination with naloxone: abuse liability and reinforcing efficacy in physically dependent opioid abusers. Drug Alcohol Depend. 2016;162:190–98. doi:10.1016/j.drugalcdep.2016.03.005.
   PubMed Web of Science ®Google Scholar
• Huskamp HA, Riedel LE, Barry CL, Busch AB. Coverage of medications that treat opioid use disorder and opioids for pain management in marketplace plans, 2017. Med Care. 2018;56:505–09. doi:10.1097/MLR.0000000000000918.
   PubMed Web of Science ®Google Scholar
• Gupta R, Shah ND, Ross JS. The rising price of naloxone—risks to efforts to stem overdose deaths. N Engl J Med. 2016;375:2213–15. doi:10.1056/NEJMp1609578.
   PubMed Web of Science ®Google Scholar
• Davis CS, Carr D. Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug Alcohol Depend. 2015;157:112–20. doi:10.1016/j.drugalcdep.2015.10.013.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration (SAMHSA). Working definition of recovery: 10 guiding principles. Rockville, MD: U.S. Department of Health and Human Services; 2012: 1–8.
   Google Scholar
• White W, Kurtz E. The varieties of recovery experience: a primer for addiction treatment professionals and recovery advocates. Int J Self Help Self Care. 2005;3:21. doi:10.2190/911R-MTQ5-VJ1H-75CU.
   Google Scholar
• Schwartz RP, Kelly SM, O’Grady KE, Mitchell SG, Peterson JA, Reisinger HS, Agar, M.H. and Brown, B.S. Attitudes toward buprenorphine and methadone among opioid‐dependent individuals. Am J Addict. 2008;17:396–401.
   PubMed Web of Science ®Google Scholar
• Polcin DL, Mericle AA, Callahan S, Harvey R, Jason LA. Challenges and rewards of conducting research on recovery residences for alcohol and drug disorders. J Drug Issues. 2016;46:51–63. doi:10.1177/0022042615616432.
   PubMed Web of Science ®Google Scholar